A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Phase of Trial: Phase III
Latest Information Update: 21 Jan 2017
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Sponsors Bayer
- 21 Jan 2017 Results (n=828) from NCT00105443 and NCT00492752 trials assessing the correlation between time to progression (TTP) and overall survival, presented at the 2017 Gastrointestinal Cancers Symposium.
- 11 Oct 2016 Results from SHARP and Asia Pacific trials assessing the association of overall survival with tumor growth rate (TGR) presented at the 41st European Society for Medical Oncology Congress.
- 10 Jan 2012 Results of subgroup analyses published in the European Journal of Cancer.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History